Form 4: iRhythm CAO Sells Shares via 10b5-1 Plan

iRhythm Technologies' Chief Accounting Officer, Marc Rosenbaum, sold 226 shares of common stock for $158.93 per share under a pre-arranged trading plan.

Summary

• Marc Rosenbaum, Chief Accounting Officer of iRhythm Technologies, Inc. (IRTC), sold 226 shares of the company's common stock.
• The transaction occurred on August 11, 2025, at a price of $158.93 per share.
• The sale was executed under a Rule 10b5-1 trading plan, which was established on May 12, 2025.
• Following this transaction, Marc Rosenbaum directly owns 10,879 shares of iRhythm Technologies common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a Rule 10b5-1 trading plan, which is a pre-scheduled transaction and does not typically indicate a change in management's outlook on the company's performance.

Positives

• Sale executed under a pre-established Rule 10b5-1 trading plan, indicating a planned transaction rather than a reactive sale.

Negatives

• An insider sale, even if pre-planned, reduces the insider's direct ownership in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but generally neutral given the 10b5-1 plan.

Key Dates

Recommendation

This Form 4 reports a pre-scheduled insider stock sale under a Rule 10b5-1 plan, which is a common practice for executives to manage their equity holdings. Such a transaction is generally considered a neutral event and does not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Investors should consider broader company performance and market conditions.

Keywords

iRhythm Technologies, IRTC, Marc Rosenbaum, Chief Accounting Officer, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Medical Devices, Healthcare Technology